QurAlis Corp. in Cambridge, Mass. announced on Nov. 19 that it raised an extension of its seed financing, bringing the round's total to $5.5m, which will help the company take its precision medicines for the treatment of amyotrophic lateral sclerosis, frontotemporal dementia and other neurological diseases from preclinical to clinical testing. QurAlis also said it won a Pfizer Inc.-sponsored "golden ticket" to occupy space in the LabCentral incubator in Cambridge and it has become a resident of the [Johnson & Johnson Innovation - JLABS] incubator. Pfizer Ventures upped its commitment to invest in neuroscience start-ups earlier this year and maintained its partnership with LabCentral. (Also see "Finance Watch: Pfizer Ventures' Dalton Makes Sense Of Neuroscience Focus Within New $600m VC Fund Commitment" - Scrip, 13 June, 2018.) Amgen Inc. provided QurAlis with its first LabCentral golden ticket in 2017. (Also see "Green Shoots: Pharma Investments In Early Innovation Support Biotech Growth" - Scrip, 24 June, 2016.)

Finance Watch: Alphamab's $100m Series A Continues Theme Of Big Investments In China Biopharma

More from Financing

More from Business